MedPath

Jiangsu Simcere Pharmaceutical Co,. Ltd.

Jiangsu Simcere Pharmaceutical Co,. Ltd. logo
🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Continuous Endostar Infusion Combined With Radiotherapy in Patients With Brain Metastases

Phase 2
Conditions
Brain Metastases
Interventions
Radiation: 6MV-X ray
First Posted Date
2011-08-05
Last Posted Date
2013-04-24
Lead Sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Target Recruit Count
80
Registration Number
NCT01410370
Locations
🇨🇳

The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China

Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients

Phase 2
Conditions
Esophageal Cancer
Interventions
Radiation: Radiotherapy
First Posted Date
2011-06-08
Last Posted Date
2013-04-24
Lead Sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Target Recruit Count
40
Registration Number
NCT01368419
Locations
🇨🇳

The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China

Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites

Phase 2
Completed
Conditions
Malignant Ascites
Malignant Pleural Effusion
Interventions
First Posted Date
2011-04-01
Last Posted Date
2014-08-01
Lead Sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Target Recruit Count
336
Registration Number
NCT01327235
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

🇨🇳

The Affiliated Hospital of Medical College, QingDao University, Qingdao, China

🇨🇳

The 81st Hospital of Chinese PLA, Nanjing, China

Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension

Phase 4
Completed
Conditions
Essential Hypertension
Interventions
First Posted Date
2010-05-27
Last Posted Date
2011-06-01
Lead Sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Target Recruit Count
1080
Registration Number
NCT01131546
Locations
🇨🇳

Peking University People's Hospital, Beijing, China

Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia

Phase 2
Completed
Conditions
Chronic Lymphocytic Leukemia
Interventions
First Posted Date
2010-04-23
Last Posted Date
2013-08-23
Lead Sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Target Recruit Count
147
Registration Number
NCT01109264
Locations
🇨🇳

Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath